Concepedia

Jan Lehmann

JL

Statistics

Publications

1

Citations

32

H-Index

1

Active since

2018

Affiliations

Kaiser-Franz-Josef-Spital(Current)

Jan Lehmann is an author at Kaiser-Franz-Josef-Spital specializing in toxicity management, metastatic cancer management, and open-label trials.

Publications per year

2018–2018

1

Publications

1

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)

Margitta Retz, Jens Bedke, Martin Bögemann et al. · European Journal of Cancer · 2018 · 32 citations

Medicine, Oncology, Pharmacology +12

1–1 of 1